Autopsy report · NCT04371406

Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients

“Regulatory approvals have not been obtained”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Assistance Publique - Hôpitaux de Paris

Sponsor type

University, hospital or other

Conditions

Covid-19

Interventions

Hydroxychloroquine and Azithromycin; Azinc

Participants

0

Trials that died the same way

• Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma
  “Study not submitted to regulatory authorities” (70% match in meaning)
• Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs
  “no approval” (68% match in meaning)
• Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - A Study in "Split Wound Design"
  “no approval by CA” (68% match in meaning)
• Precision Medicine Approach to Unravel the Risk Factors for Renal, Cardiovascular, Ophthalmologic, Neurologic and Hepatic Complications of Metabolic Disorders
  “No inclusion within 2 years of approval by CPP” (62% match in meaning)
• Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
  “No approval from ethical committee” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.